Brain Neoplasms Clinical Trial
Official title:
Pilot Study Evaluating the Feasibility of Real-Time, Magnetic Resonance Thermal Imaging and Magnetic Resonance Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors
In this study, the Visualase Thermal Therapy System will be used on metastatic brain tumors that cannot be removed by surgery. Researchers want to find out if it is possible to use this new device in subjects with 1-3 metastatic brain tumor(s), each measuring 3 centimeters (cm) or smaller. The safety of the device will also be studied.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | September 2010 |
Est. primary completion date | September 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Patient or family able and willing to give informed consent. - Subjects with metastatic cancer to the brain who have failed at least one conventional therapy (surgery, stereotactic radiosurgery, and/or whole brain radiotherapy). - Three or fewer previously treated or untreated lesion(s) in the brain. - Tumor size = 3.0 cm in largest diameter. - MR imaging is not contraindicated for the patient. - Lesion(s) are clearly defined on pre-therapy contrast enhanced MRI scans as determined by the treating surgeon. - Able and willing to attend all study visits. - Karnofsky Performance Scale score >70 for patients over the age of 15. - Lansky Play Scale >70 for patients 15 years of age or younger. Exclusion Criteria: - Patients or family unwilling or unable to give written consent. - Patients who cannot physically fit in, or are too heavy for, the MRI scanner. - Patients with contra-indications to MRI imaging, such as, but not limited to, pacemakers or defibrillators, non-compatible aneurysm clips, shrapnel, or other internal ferromagnetic objects. - Known sensitivity to gadolinium-DTPA. - Based on Treatment Planning Imaging (MR and/or CT): - Brain edema and/or mass effect that causes midline shift or shift in wall of ventricle of more than 5 mm. - Lesions localized in the brain stem. - Lesions less than 5mm from primary branches of cerebral vessels, venous sinus, hypophysis or cranial nerves. - Evidence of recent (<2 weeks) hemorrhage. - Presence of more than 3 brain tumors at the time of enrollment. - Symptoms and signs of increased intracranial pressure. - Medical issues which prohibit the patient from undergoing surgery (as determined by the treating surgeon, anesthesiologist, IMPAC clinic, referring physician). - Patients who are unable to receive corticosteroids. - Positive pregnancy test for women of child-bearing age. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | North Shore University Hospital | Manhasset | New York |
Lead Sponsor | Collaborator |
---|---|
Visualase, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of technical success or failure to complete the initial procedure with no associated major complications. | within 24 hours following the procedure | No | |
Secondary | Examination of the extent to which Visualase predictions based on MRTI data match lesion dimensions form post-therapy MRI assessments. | Immediately following treatment (day 0) | No | |
Secondary | Estimates of durations, required facilities, required personnel, and costs for all aspects of the treatment procedure | from day 0 to patient release | No | |
Secondary | Local control of treated lesions as defined by volume of lesions increasing by no more than 25% | Day 30, 90, and 180 days post procedure | No | |
Secondary | Accrual of patient survival post Visualase therapy | Sooner of 3 years or patient death | No | |
Secondary | Procedure-related morbidity and mortality | 30, 90,180 days post procedure | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02810899 -
Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy
|
Phase 4 | |
Withdrawn |
NCT00977795 -
A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00555984 -
Intravenous Anesthesia Versus Anesthesia With Volatile Agents in Elective Craniotomy for Tumors
|
N/A | |
Completed |
NCT00038441 -
Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas
|
Phase 1/Phase 2 | |
Recruiting |
NCT03619694 -
Role of MR Spectroscopy in Brain Tumors
|
||
Withdrawn |
NCT01236586 -
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
|
Phase 1 | |
Unknown status |
NCT02775136 -
An Evaluation of a Non-invasive Brain Monitor
|
N/A | |
Completed |
NCT01244737 -
FLT-PET Imaging of Brain Tumors in Children
|
Phase 2 | |
Completed |
NCT00993057 -
Efficiency of Two Glucose Sampling Protocols for Maintenance of Euglycemia
|
Early Phase 1 | |
Terminated |
NCT00769093 -
Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy
|
Phase 1 | |
Completed |
NCT00392119 -
MR Guided Laser Interstitial Thermal Therapy for the "Minimal Invasive" Treatment of Brain Metastasis and Primary Brain Tumors
|
Phase 1 | |
Completed |
NCT00062478 -
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
|
Phase 2 | |
Terminated |
NCT00038389 -
Study of Vioxx and Radiation Therapy for Brainstem Glioma
|
Phase 1 | |
Recruiting |
NCT05049148 -
Platelets Activation in Brain Neoplasms
|
N/A | |
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Recruiting |
NCT04712721 -
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
|
Early Phase 1 | |
Completed |
NCT02881957 -
Hypovitaminosis D in Neurocritical Patients
|
Phase 2/Phase 3 | |
Terminated |
NCT01954576 -
NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
|
N/A | |
Recruiting |
NCT05538130 -
A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04111588 -
Diagnostic Assessment of Amino Acid PET/MRI in the Evaluation of Glioma and Brain Metastases
|